Mismanaged Oral Cancer Leads to Neutropenia and Death

Case Overview

This case involves a fifty-nine-year-old man who was diagnosed with squamous cell carcinoma of the mouth and tongue. The cancer was stage III at the time of diagnosis and the oncologist on the patient’s case sought the input from several other doctors to help manage the patient’s care. The plan was for the patient to have the remainder of his teeth extracted prior to beginning chemotherapy and external beam radiation. The doctors involved were a medical oncologist, a radiation oncologist, a dentist, and an oral surgeon. The patient’s teeth were extracted and he was admitted to the hospital that day to begin the chemotherapy. He was hospitalized for five days to receive the treatment and was then discharged home to recover. Two days later, he was re-hospitalized for severe neutropenia and died shortly after as a result of being severely immunocompromised.

Questions to the Hematology expert and their responses

Could prophylactic antibiotics have changed the outcome of this case?

Medical care for patients with neutropenia is mostly supportive and based on the etiology, severity, and duration of the neutropenia. Fever and infections occurring as complications of chemotherapy induced neutropenia require specific treatment. It is important to promptly start prophylactic antibiotic therapy to combat potential infections in the immunocompromised state. This often involves the use of third-generation cephalosporins or equivalents and I suspect that this patient died from a lack of preemptive treatment.

About the expert

This expert is board certified in Hematology & Oncology with additional research training in hereditary breast and ovarian cancers. He received his medical training at the Long Island Jewish Hillside Hospital Medical Center was formerly the Clinical Professor in the Department of Hematology & Oncology at a major university medical center in New York. Furthermore, he is currently on staff as an affiliated attending with privileges at several New York Hospital and is also the director of Medical Oncology at a private practice.

E-000029

Specialties:

Hematology

Michael Talve stands at the forefront of legal innovation as the CEO and Managing Director of Expert Institute. Under his leadership, the Expert Institute has established itself as a vital player in the legal technology arena, revolutionizing how lawyers connect with world-class experts and access advanced legal technology. Michael's role involves not only steering the company's strategic direction but also ensuring the delivery of unparalleled intelligence and cutting-edge solutions to legal professionals. His work at Expert Institute has been instrumental in enhancing the capabilities of attorneys in case preparation and execution, making a significant impact on the legal industry's approach to expert consultation and technological integration. Michael's vision and execution have positioned the Expert Institute as a key facilitator in the intersection of law and technology.